Bang, Yung-Jue <br/><br/>
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 2015 
 - 3858-65 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2014.60.0320  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--classification<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Ataxia Telangiectasia Mutated Proteins--blood<br/>Biomarkers, Tumor--blood<br/>Biopsy, Needle<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--classification<br/>Paclitaxel--administration & dosage<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Stomach Neoplasms--classification<br/>Survival Analysis<br/>Treatment Outcome